FRONTIER BIOTECHNOLOGIES Inc.
PhD John Hopkins Univ.
Executive Director Biocalorimetry Center at John Hopkins; Director Biophysics Lab at National Cancer Institute/NIH
Global Project Leader and R&D Director at Tibotec (acquired by J&J), led three novel anti-HIV drug development
PhD College of Pharmacy, Univ. of Kentucky
>20+ years R&D and business development experience in US
VP BD at Vivus (Nasdaq: VVUS), Abmaxis (acquired by Merck) and TaiGen Biotech; VP Marketing and BD at Cellomics; Director BD and M&A at Packard Bioscience; Principal Scientist at Merck
PhD Nankai Univ., Postdoc Northeastern Univ. / Harvard Medical School; Sr. postdoctoral fellow at NCI
Principal Research Investigator / Project Leader at Sequoia and Trimeris; Senior Scientist at Tibotec
Led and participated in CMC development of several anti-HIV drugs including T-20 and Darunavir>
PhD Western Ontario Univ.
Pharmaceutical executive with 24+ years experience in drug development, CMC, Quality and management at MabPlex, Adellos, Omeros, and AbbVie
MD, MS pharmacology, Fudan Univ. Medical School
20+ years experience in clinical development and medical affairs; Former Head of Medical at Bayer (China)
BS economics Southeastern Univ. MS Finance Shanghai Univ.
10+ years experience in finance, auditing, taxation, investment and M&A at BASF and Continental
MBA CEIBS; CPD Wharton School, Univ. Penn
20+ years global BD&MA experience; Former CIO at Fosun Pharma; Global Marketing Dir. at Bayer (US)
BS Lanzhou Univ., MBA Nanjing Univ.
20+ years of marketing, sales, and market access experience at Pfizer (China) and Novartis (China)
MBA, London School of Economics; Executive Program with Harvard, IMD, INSEAD
25+years of commercial, general management experience across Regional (APAC) & Global emerging markets at Sanofi, Abbott and GSK
PhD Peking Univ.
10+ years drug development experience at Pfizer and Wyeth; 6+ years at US FDA
Member of the Quality Guidelines Expert in ICH Technical Requirements at CDE of NMPA